Flash Report: JDRF Research Grant Funding Lowest Level in 10 Years

December 3, 2014

JDRF's financial statements are important because they show how the money provided by donors is actually utilized. This short report highlights a few key trends. Click here to read more. 


Flash Report: Partnering for Faster Cures Conference

November 19, 2014

We attended the Partnering for Cures 2014 Conference held in New York City on November 18th and 19th.  While we attended many different sessions, there were three main takeaways from a majority of panels. Click here to read more. 

 


NUVILEX "BREAKTHROUGH" IN PERSPECTIVE: GOOD DIRECTION BUT YEARS FROM HUMAN TRIALS 

November 13, 2014

The US biotech company Nuvilex made recent news when it obtained exclusive rights to use insulin-producing "Melligen" cells to develop a treatment and possible cure for type 1 diabetes. Here we apply a Practical Cure perspective to give some background on the technology.  Click here to read more. 

 


Why Do we walk? Insights from the T1D community

October 21, 2014

A recent JDCA survey polled the T1D community to examine why people participate in diabetes fundraising walks and what makes these walks so successful.  This report addresses why people walk, what they expect from walks, and how these events are so effective at generating revenue. Click here to read more. 


A Practical Cure Perspective on Doug Melton's Research

OCTOBER 15, 2014

Dr. Douglas Melton, co-director of the Harvard Stem Cell Institute, and his colleagues published a paper in the October 9th issue of Cell detailing their recent generation of insulin-producing beta cells from stem cells. We share some background about the research and evaluate the findings from a Practical Cure perspective.  Click here to read more. 


Board Accountability may be the key to a cure

OCTOBER 1, 2014

This report discusses the role of the board of directors at the major type 1 diabetes non-profits. At the end of the report, five recommendations are suggested for the boards to adopt to increase effectiveness and, hopefully, speed to a cure. Click here to read more. 


87% of Major Fundraising Events Held by JDRF and THE ADA Promise a Cure

September 23, 2014

Although donors prioritize cure research and 87% of events promise to further a cure, our latest report reveals that only a small percentage of the proceeds from fundraising events actually goes toward T1D cure research.  Click here to read more. 


Executive Compensation: Helping or Hurting Cure Progress?

September 4, 2014

This is the JDCA's annual report on executive compensation at the principle diabetes non-profits and research centers.  The report demonstrates that only a minority of pay is based on performance while the majority of pay is guaranteed whether or not the organization makes progress toward its mission.  Click here to read more. 


ADA 2013 Financial Review: Is any money going to type 1?

August 21, 2014

In fiscal year 2013, the ADA spent 84% of their budget on non-research activities, mostly advocacy, publications, and fundraising. The ADA did not allocate a single dollar to type 1 Practical Cure research projects in 2013, and only gave an estimated 6% of the budget to any kind of type 1 research at all. Click here to read more. 


Flash Report: Viacyte Approved for Human Trials

august 20, 2014

Yesterday, ViaCyte announced that they will enter into human trials during the next few months.  This initiative combines both cell supply (via stem cells) and cell protection (encapsulation device) into one solution. The JDCA classifies this initiative as a potential Practical Cure.  Click here to read more. 


JDRF 2013 Research Grant Allocations: 3% of Revenue Used for Practical Cure

August 5, 2014

This report reviews the JDRF's research grant allocations during fiscal year 2013.  In doing the analysis, we were surprised to find that only 3% of their grant allocations went towards Practical Cure progress. This is not a meaningful portion of their budget, and this goes against what our research has shown donors want.  Click here to read more. 


JDRF 2013 Annual Research Spending Down by $50 million Since 2008 Peak

July 22, 2014

This report reviews the JDRF's revenue and spending during fiscal year 2013.  In doing the analysis, we were surprised to find that annual spending on T1D research was reduced by $50 Million compared to 2008.  At the same time, all other spending categories increased.  Obviously, in our view, this trend does not align with donor interests, who prioritize spending on cure research over all else. Click here to read more. 


FLASH REPORT: ADA Conference Recap

July 3, 2014

Last week JDCA fellow Joshua Levy took a trip to the 2014 ADA Scientific Conference to see what new Practical Cure and type 1 research may be occurring. What did he discover?  Click here to read more. 


Donor Sentiment a Mixed Bag

June 24, 2014

Donor Sentiment a Mixed Bag: Active in Fundraising But Weak In Confidence takes a deeper look into the influences of donor sentiment within the type 1 diabetes community. Click here to read more. 


FLASH REPORT: Merck Smart Insulin Ready for Human Trials

May 21, 2014

Attached is a short Flash Report responding to the recent news that Merck is preparing to enter it's Smart Insulin project into human testing. This report provides a practical perspective , identifying what is genuinely hopeful about the project as well as the key questions that need to be addressed.  Click here to read more. 


FLASH REPORT: Damiano, Faustman, and the T1D Exchange

may 9, 2014

This week we visited Boston to get updates on several Practical Cure projects, and attend the T1D Exchange.  Click here to read more. 


Update on Practical Cure Projects in Human Clinical TrialS

April 30, 2014

This week we're giving updates on all of the Practical Cure projects currently in Human Clinical Trials with the help of Joshua Levy, JDCA Fellow and longtime type 1 cure research analyst.  Click here to read more. 


An Overview of the Type 1 Diabetes Cure Platforms

April 16, 2014

This week we're taking a look at the pathways to a type 1 cure, with special guest writer Joshua Levy. We also point out some of the pathways that could lead to a Practical Cure.  Look for a follow-up in May where we take a deep dive and investigate the projects along these pathways.  Click here to read more. 


Flash Report: OUr Response to NY Times Diabetes Article

April 11, 2014

Earlier this week, the New York Times ran an article titled "Even Small Medical Advances Can Mean Big Jumps in Bills." It ignited controversy in the diabetes world, and below is a quick summary and implications for a Practical Cure.  Click here to read more. 


A Look at Commercial Practical Cure Prospects

March 13, 2014

This report offers a representative look at smaller commercial enterprises pursuing pathways that may result in a Practical Cure. Click here to read more. 


Cure Attitudes and Trends Survey: Donors Value Speed and focus

March 3, 2014

The JDCA recently completed a survey to find out what donors value when it comes to cure research. Read all of our findings in our latest report. Click here to read more. 


A visit to the diabetes research institute

February 7, 2014

This week the JDCA visited the Diabetes Research Institute to learn more about the current status of the BioHub. Click on the links to get a quick run-down of the key findings. Click here to read more. 


JDCA West Coast Research Trip

January 22, 2014

Last week the JDCA visited the West Coast  to meet with several of the largest type 1 diabetes research centers and to attend the 2014 JP Morgan Healthcare Conference.  Click on the links to get a quick run-down of the key findings. Click here to read more.